Products for Research Use Only

Astegolimab

CAT: 0804-HY-P99444-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99444-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research[1][2][3].
CAS Number
2173054-79-8
Product Name Alternative
MSTT 1041A; RG 6149
UNSPSC
12352203
Target
Interleukin Related; MDM-2/p53; NF-κB
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Immunology/Inflammation; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/astegolimab.html
Purity
99.00
Solubility
H2O
Smiles
[Astegolimab]
Molecular Weight
(144.98 kDa)
References & Citations
[1]Steven G Kelsen, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol. 2021 Sep;148 (3) :790-798.|[2]Yi N, et al. Lenvatinib-activated NDUFA4L2/IL33/PADI4 pathway induces neutrophil extracellular traps that inhibit cuproptosis in hepatocellular carcinoma. Cell Oncol (Dordr) . 2025 Apr;48 (2) :487-504.|[3]Wu L, et al. Mechanistic role of RND3-regulated IL33/ST2 signaling on cardiomyocyte senescence. Life Sci. 2024 Jul 1;348:122701.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Isoform
IL-33

Popular Products